Position in CDNA
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$725,040
+$278,740 QoQ
Shares Held
25,440
+7.4% QoQ
Ownership
0.049%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#111
of 225 holders
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CDNA Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $16,598,580 across 18 Diagnostics & Research names. CDNA ranks #10 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NTRA |
Natera, Inc.
|
11,336 | $3,077,157 | |
| 2 | TMO |
Thermo Fisher Scientific Inc.
|
4,702 | $2,357,394 | |
| 3 | GH |
Guardant Health, Inc.
|
11,811 | $1,772,004 | |
| 4 | BDSX |
Biodesix Inc
|
46,989 | $1,059,601 | |
| 5 | DGX |
Quest Diagnostics Inc
|
4,971 | $1,053,603 | |
| 6 | IDXX |
Idexx Laboratories Inc /De
|
1,981 | $1,042,877 | |
| 7 | XGN |
Exagen Inc.
|
214,721 | $998,452 | |
| 8 | MTD |
Mettler Toledo International Inc/
|
619 | $790,778 |
All Filings in CDNA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $725,040 | 25,440 | Shares | Sole | 2026-08-06 | |
| 2025-12-31 | $446,300 | 23,689 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $445,941 | 30,670 | Shares | Sole | 2025-11-07 | |
| 2024-03-31 | $185,632 | 17,529 | Shares | Sole | 2024-05-03 | |
| 2023-12-31 | $219,504 | 18,292 | Shares | Sole | 2024-02-16 | |
| 2023-09-30 | $462,098 | 66,014 | Shares | Sole | 2023-11-15 | |
| 2023-06-30 | $384,897 | 45,282 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $1,609,197 | 176,061 | Shares | Sole | 2023-05-12 | |
| 2020-03-31 | $252,878 | 11,584 | Shares | Sole | 2020-05-12 | |
| No filing history on record for this holder in this stock. | ||||||